A2aR x PDE2A

Primary objective: To compare the differences in absorption extent and rate between the doxofylline tablets produced by Hefei Heyuan Pharmaceutical Co., Ltd. and the doxofylline tablets (trade name: ANSIMAR®, specification: 0.4g) licensed by ABC FARMACEUTICI S.P.A. in healthy adults under fasting and high-fat meal administration conditions using pharmacokinetic parameters as endpoints, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of oral administration of the test preparation doxofylline tablets and the reference preparation doxofylline tablets in healthy subjects under fasting and high-fat meal administration conditions.

The primary objective was to compare the differences in the extent and rate of absorption of the doxofylline tablets produced by Hefei Heyuan Pharmaceutical Co., Ltd. and the doxofylline tablets (trade name: ANSIMAR, specification: 0.4g) licensed by ABC FARMACEUTICI S.P.A. in healthy adults under fasting conditions using pharmacokinetic parameters as endpoints, and to evaluate the bioequivalence of the two preparations. The secondary objective was to evaluate the safety of the test preparation doxofylline tablets (specification: 0.4g) and the reference preparation doxofylline tablets (trade name: ANSIMAR, specification: 0.4g) in healthy subjects when taken orally.

Main study objectives: To study the pharmacokinetics of the test preparation Doxofylline Tablets (Specification: 400mg, Heilongjiang Fuhe Pharmaceutical Group Co., Ltd. Heilongjiang Fuhe Pharmaceutical Group Co., Ltd.) and the reference preparation Doxofylline Tablets (Trade name: ANSIMAR®, Specification: 400mg, ABC FARMACEUTICI S.P.A.) in healthy adult subjects after a single oral administration under fasting conditions, and to evaluate the bioequivalence of the two preparations after oral administration under fasting conditions. Secondary study objectives: To evaluate the safety of the test preparation (T) Doxofylline Tablets and the reference preparation (R) Doxofylline Tablets (Trade name: ANSIMAR®) after a single oral administration under fasting conditions in healthy subjects.